Mable
Reduces migraines by individualizing treatment to the DNA.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
* | $3.2m | Seed | |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Mable is a pioneering startup in the healthcare sector, specifically targeting individuals suffering from migraines. The company leverages advanced genomic research to offer personalized migraine treatments. By analyzing a patient's DNA and migraine history, Mable tailors a treatment plan that is customized to the individual's unique genetic makeup and specific migraine triggers. This approach aims to increase the effectiveness of migraine treatments, providing relief where traditional methods may have failed.
Mable primarily serves individuals who experience chronic migraines and are seeking more effective, personalized treatment options. The company operates in the health and wellness market, with a focus on precision medicine—a field that uses genetic information to guide treatment decisions.
The business model of Mable is direct-to-consumer. Clients begin by taking a DNA test, which is painless and straightforward. They then complete an online medical assessment to provide further details about their migraine history. Based on this information, Mable's team of neurologists and headache specialists, who are affiliated with prestigious institutions like Harvard and King's College, create a customized treatment plan. This plan is then delivered directly to the client's door, ensuring continuous access to expert care.
Mable generates revenue through the sale of these personalized treatment plans. Clients pay for the initial DNA test and the ongoing delivery of their customized medications. The company also offers continuous support from their medical advisory board, which includes renowned headache experts.
In summary, Mable is revolutionizing migraine treatment by combining genomic science with clinical expertise to offer individualized care. This approach not only aims to improve the quality of life for migraine sufferers but also represents a significant advancement in the field of personalized medicine.
Keywords: Migraine, Personalized Treatment, Genomics, DNA Test, Neurology, Direct-to-Consumer, Precision Medicine, Healthcare, Chronic Pain, Medication Delivery.